GARY SHEARMAN, Ph.D.
PRESIDENT & CHIEF EXECUTIVE OFFICER
DIRECTOR
Dr. Shearman brings more than 25 years of biopharmaceutical industry experience. Dr. Shearman has been responsible for creating and implementing global drug development and regulatory strategies which have resulted in over twenty regulatory submissions and product approvals worldwide. Dr. Shearman also brings extensive insight into the biopharmaceutical market having spent the past six years as a venture capitalist and consultant to biotechnology companies, including over five years as Chairman and Managing Director of HBM Advisors USA, LLC, a provider of investment advisory services to HBM BioVentures and HBM BioCapital in the biotechnology and medical technology sectors.

Between May 1992 and January 2000, Dr. Shearman was employed by Rhône-Poulenc Rorer (now Sanofi/Aventis) where he served in a variety of positions, most recently as Deputy Head of Global Research and Drug Development and Senior Vice President of Global Drug Development. He was responsible for ensuring the global implementation of the corporate product strategy and coordinating all R&D, marketing and manufacturing activities related to the widely used cardiovascular and oncology drugs Lovenox® and Taxotere®. He also served as Senior Vice President of Pharmaceutical Drug Development for Rhône-Poulenc Rorer where he coordinated global drug development and regulatory strategies and directed global departments with over 2,200 employees and a consolidated annual budget of approximately $450 million.

From 1987 to 1992, Dr. Shearman worked at Merck & Co., Inc. where he served as Director of International Regulatory Affairs and prior to that as Associate Director, Clinical Neurosciences. Dr. Shearman’s began his pharmaceutical career at Sandoz, Ltd., a Swiss pharmaceutical company (now a part of Novartis) where he worked in drug discovery and as a project leader for central nervous system products.

Dr. Shearman earned his Ph.D in Pharmaceutical Sciences at the University of Rhode Island. He did his post-doctoral studies in the Department of Neuropharmacology at the Max Planck Institute for Psychiatry in Munich, Germany. Dr. Shearman is Chairman of the Board of Directors of Nereus Pharmaceuticals, Inc., a privately held biopharmaceutical company.

DAVID BARRETT
CHIEF FINANCIAL OFFICER
Mr. Barrett joined Neuro-Hitech from Overture Financial Services (“Overture”), where he served as the Chief Financial Officer for Overture's registered investment advisor. Previously, Mr. Barrett was Chief Financial Officer at Overture Asset Managers, LLC where he was responsible for managing the finances, business, acquisition and operation strategy for the firm and its affiliates. Prior to Overture Asset Managers, Mr. Barrett was with Deloitte & Touche, where he worked in the audit practice and consulting group. Mr. Barrett is a member of the New York and Connecticut Public Accountant Associations.


L. WILLIAM MCINTOSH
Mr. McIntosh, a 30-year veteran of the pharmaceutical and biotechnology industries, has a skill set that spans marketing, sales, business development, product development and general management. Mr. McIntosh was previously CEO of Q-RNA and has also served in senior positions at Merck and Co. Inc., Medco Containment Services, Boehringer Mannheim Pharmaceuticals Corporation, Zynaxis, Inc., Smith Kline Beecham Pharmaceuticals, and Nexell Therapeutics, Inc. He was also president and CBO for FASgen. Mr. McIntosh received both his B.S. and M.B.A. from Lehigh University in Pennsylvania.

WILLIAM WONG, Ph.D.
Mr. Wong, Ph.D., brings a special blend of science and business development skills, having served in management positions at large, medium and early-stage companies. Dr. Wong’s experience encompasses research, product development, regulatory, technical evaluation, business development and in- and out-licensing. A 20+-year veteran of the pharmaceutical, biotechnology, diagnostics and device industries, he began his career at Becton-Dickinson Corporation and moved to E.I. Dupont Co.’s Extracorporeal Therapy Systems division. He also served on senior management teams at Zynaxis, Inc., Intracel Corporation, Nexell Therapeutics, and Lynx Therapeutics, Inc. Dr. Wong was most recently VP for product development at Q-RNA. He received his Ph.D. from the University of Rochester School of Medicine in the Department of Microbiology and Immunology.